Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)
Japan
· Delayed Price · Currency is JPY 1,287.00
-8.00 (-0.62%)
May 20, 2025, 3:30 PM JST
TYO:2395 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 32,414 | 26,450 | 25,090 | 17,748 | 15,110 | Upgrade
|
| Revenue Growth (YoY) | 22.55% | 5.42% | 41.37% | 17.46% | 3.77% | Upgrade
|
| Cost of Revenue | 17,813 | 12,168 | 12,044 | 8,061 | 7,557 | Upgrade
|
| Gross Profit | 14,601 | 14,282 | 13,046 | 9,687 | 7,553 | Upgrade
|
| Selling, General & Admin | 8,700 | 8,116 | 6,830 | 4,908 | 4,482 | Upgrade
|
| Research & Development | 2,218 | 1,741 | 683 | 425 | 392 | Upgrade
|
| Operating Expenses | 11,616 | 10,120 | 7,801 | 5,491 | 5,024 | Upgrade
|
| Operating Income | 2,985 | 4,162 | 5,245 | 4,196 | 2,529 | Upgrade
|
| Interest Expense | -202.75 | -138 | -125 | -126 | -184 | Upgrade
|
| Interest & Investment Income | 98.86 | 188 | 58 | 8 | 2 | Upgrade
|
| Earnings From Equity Investments | 3,513 | 2,751 | 2,489 | 1,439 | 846 | Upgrade
|
| Currency Exchange Gain (Loss) | -162.7 | 60 | 1,511 | 1,370 | 239 | Upgrade
|
| Other Non Operating Income (Expenses) | 219.1 | -7 | 16 | 190 | 211 | Upgrade
|
| EBT Excluding Unusual Items | 6,451 | 7,016 | 9,194 | 7,077 | 3,643 | Upgrade
|
| Gain (Loss) on Sale of Investments | -130.89 | 51 | -1,327 | 1,381 | 1,173 | Upgrade
|
| Gain (Loss) on Sale of Assets | -228.8 | -50 | -13 | -21 | -4 | Upgrade
|
| Asset Writedown | -78.13 | -34 | -44 | -225 | -639 | Upgrade
|
| Other Unusual Items | - | -9 | -51 | -30 | - | Upgrade
|
| Pretax Income | 6,013 | 6,974 | 7,759 | 8,182 | 4,173 | Upgrade
|
| Income Tax Expense | 1,149 | 1,456 | 1,708 | 1,016 | 497 | Upgrade
|
| Earnings From Continuing Operations | 4,865 | 5,518 | 6,051 | 7,166 | 3,676 | Upgrade
|
| Minority Interest in Earnings | 60.26 | 13 | 9 | -39 | -15 | Upgrade
|
| Net Income | 4,925 | 5,531 | 6,060 | 7,127 | 3,661 | Upgrade
|
| Net Income to Common | 4,925 | 5,531 | 6,060 | 7,127 | 3,661 | Upgrade
|
| Net Income Growth | -10.96% | -8.73% | -14.97% | 94.67% | 43.57% | Upgrade
|
| Shares Outstanding (Basic) | 42 | 42 | 42 | 42 | 42 | Upgrade
|
| Shares Outstanding (Diluted) | 42 | 42 | 42 | 42 | 42 | Upgrade
|
| Shares Change (YoY) | 0.00% | - | -0.00% | - | - | Upgrade
|
| EPS (Basic) | 118.30 | 132.86 | 145.56 | 171.19 | 87.94 | Upgrade
|
| EPS (Diluted) | 118.30 | 132.86 | 145.56 | 171.19 | 87.94 | Upgrade
|
| EPS Growth | -10.96% | -8.73% | -14.97% | 94.67% | 43.57% | Upgrade
|
| Free Cash Flow | -3,607 | -6,476 | -834 | 4,410 | 3,679 | Upgrade
|
| Free Cash Flow Per Share | -86.64 | -155.56 | -20.03 | 105.93 | 88.37 | Upgrade
|
| Dividend Per Share | 50.000 | 50.000 | 50.000 | 30.000 | 10.000 | Upgrade
|
| Dividend Growth | - | - | 66.67% | 200.00% | 100.00% | Upgrade
|
| Gross Margin | 45.05% | 54.00% | 52.00% | 54.58% | 49.99% | Upgrade
|
| Operating Margin | 9.21% | 15.73% | 20.91% | 23.64% | 16.74% | Upgrade
|
| Profit Margin | 15.19% | 20.91% | 24.15% | 40.16% | 24.23% | Upgrade
|
| Free Cash Flow Margin | -11.13% | -24.48% | -3.32% | 24.85% | 24.35% | Upgrade
|
| EBITDA | 5,596 | 6,029 | 6,845 | 5,373 | 3,716 | Upgrade
|
| EBITDA Margin | 17.27% | 22.79% | 27.28% | 30.27% | 24.59% | Upgrade
|
| D&A For EBITDA | 2,611 | 1,867 | 1,600 | 1,177 | 1,187 | Upgrade
|
| EBIT | 2,985 | 4,162 | 5,245 | 4,196 | 2,529 | Upgrade
|
| EBIT Margin | 9.21% | 15.73% | 20.91% | 23.64% | 16.74% | Upgrade
|
| Effective Tax Rate | 19.10% | 20.88% | 22.01% | 12.42% | 11.91% | Upgrade
|
Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.